Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation
Click CC to turn on closed captioning.
Published: January 2011Print Record of Viewing
Dr. McKeon reviews the diagnostic testing algorithm for autoimmune gastrointestinal dysmotility (AGID), defines the clinical utility of an AGID evaluation, and describes interpretation of laboratory testing.
Presenter: Andrew McKeon, MB, BCh, MD
- Consultant in the Neuroimmunology Laboratory in the Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota
Questions and Feedback
Contact us: .
Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.
Our presenter for this program is Andrew McKeon, MB BCh (N-AI), consultant in the Neuroimmunology Laboratory in the Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota. Dr. McKeon will review the diagnostic testing algorithm for autoimmune gastrointestinal dysmotility (AGID), define the clinical utility of an AGID evaluation, and describe interpretation of laboratory testing.
This new profile is called the "autoimmune gastrointestinal dysmotility or AGID profile."
Autoimmune Gastrointestinal Dysmotility
So what is autoimmune gastrointestinal dysmotility? This is a limited form of dysautonomia with prominent gastrointestinal symptoms. In this disorder the enteric nervous system is targeted by the immune system. These disorders are mediated by neural specific IgG antibodies or by effector T-cells. These disorders may occur on an idiopathic basis or in some cases may occur associated with a systemic cancer, which is also known as a paraneoplastic disorder.
The symptoms of these autoimmune gastrointestinal disorders include early satiety, anorexia, nausea, vomiting, weight loss, constipation or diarrhea. The onset of these disorders may occur either subacutely or insidiously. Other components of the autonomic nervous system may also be affected to a greater or lesser degree. Other symptoms may include orthostatic hypotension, bladder dysfunction, dry eyes and dry mouth.
Diagnostic clues from the history could include a personal or family history of autoimmunity or cancer. Oncological associations have been seen in a paraneoplastic context in patients with autoimmune gastrointestinal dysmotility include carcinomas (usually of the lung), breast, endometrium or GI system and thymoma.
Autoimmune Gastrointestinal Dysmotility
The importance of an early diagnosis of autoimmune gastrointestinal dysmotility lies in less morbidity with early treatment. Many of these patients have a favorable response to Pyridostigmine which can improve synaptic transmission by inhibiting acetylcholinesterase. Many of these patients will improve with immunotherapies such as intravenous immunoglobulin or intravenous steroids, particularly if started early. Longer term therapy with immunosuppressants may be required if objective benefit is noted with the initial trial of therapy. Depending on the antibody or profile of antibodies detected a search for cancer may be initiated on this basis. Sometimes particular antibodies detected or a profile of antibodies detected can help identify the histological type of cancer present, and thus guide oncological investigations.
Gastrointestinal Motility Studies
So, how are patients with AGID evaluated? Since many of the symptoms that I mentioned above are quite nonspecific, when the history is suggestive of a gastrointestinal dysmotility disorder, abnormalities can be objectively documented with further testing. These tests may include slow emptying on a gastric small intestinal or colonic nuclear transit study. Also there may be abnormalities detected on esophageal gastroduodenal or colonic manometry. Also abnormalities may be found on anorectal manometry with balloon expulsion.
In that context, the autoimmune gastrointestinal dysmotility antibody evaluation can aid the diagnosis of both idiopathic autoimmune and paraneoplastic disorders and, as mentioned, multiple antibodies are commonly found coexisting together and the specific neoplasm may be predicted by the antibody profile. or example, ANNA-1 antibody with N type calcium channel antibody is predictive of small cell carcinoma.
Ganglionic Acetylcholine Receptor (AChR) Autoantibody
I will now go into a little more detail about the ganglionic alpha-3 acetylcholine receptor autoantibody since this is the most commonly encountered antibody marker of autoimmune gastrointestinal dysmotility. When this antibody is found in a patient with autoimmune gastrointestinal dysmotility this may be accompanied by other signs of dysautonomia outside of the gastrointestinal system. The antibody level or antibody value often reflects the severity of dysautonomia.
Values greater than 1.00 nanomoles per liter are usually accompanied by other signs of dysautonomia in addition to gastrointestinal dysmotility. Values between 0.03 and 0.99 nanomoles per liter the autoimmune gastrointestinal dysmotility may be isolated or signs of dysautonomia outside of the gastrointestinal system may be mild. Overall cancer is detected in 30% of seropositive patients. A variety of cancers have been associated with this antibody including adenocarcinoma, small cell carcinoma, thymoma and lymphoma.
On the next slide I am going to go through the profile and the different antibodies that are tested for. Before I do that, I am just going to briefly mention that there are 3 different types of antibodies tested for. First of all, the neuronal nuclear antibody such as ANNA-1 or antineuronal nuclear antibody type-1 which is known in the literature also as anti-hu antibody. As mentioned earlier this is associated with small cell carcinoma. Then there are another group of antibodies which have specificity for antigens in cytoplasm of nerve and muscle. These include CRMP-5, IgG, GAD-65 and striational antibody. Finally, the last group of antibodies are known as cation channel antibodies, which include ganglionic and muscle acetylcholine receptor antibodies, N type calcium channel antibody and the voltage-gated potassium channel antibody.
AGID Evaluation Testing Algorithm
So now to look at this in the format of the testing algorithm, there are some antibodies that are always tested for and these are included in the box just below ‘always performed’. These are tested for using a variety of assays including immunofluorescence, ELISA and immunoprecipitation assays. There are four situations in which additional testing may be done and these are illustrated at the bottom of the screen. I will discuss these from left to right.
The first is the immunofluorescence pattern is indeterminate. In this situation there may be an antibody staining pattern suspicious for antineuronal nuclear antibody type-1, but not all of the characteristic features are present. In that setting we will additionally do a paraneoplastic Western blot to look for the characteristic Western blot pattern associated with this antibody.
The second setting and the third setting would occur where an antibody pattern suggestive of Amphiphysin antibody or CRMP-5 IgG were detected. Then we would confirm the presence of these antibodies with recombinant Western blots for the appropriate antibody, either Amphiphysin or CRMP-5 IgG. The final setting in which additional testing may be done would be where the acetylcholine receptor binding antibody or striational antibody were detected. For this, the possibility of an antibody profile supportive of thymoma would come to mind. This could be further explored by doing testing for the acetylcholine receptor modulating antibody and CRMP-5 IgG by Western blot.
So what are the appropriate clinical circumstances to do the autoimmune GI dysmotility serological evaluation? There are five specific uses for this testing. Firstly, this testing can be used for investigating acquired idiopathic gastrointestinal dysmotility to see if an idiopathic autoimmune or paraneoplastic basis can be established for this. This can then help direct treatment. If one or more of the antibodies described were detected, this may increase the clinician’s confidence that a trial of immunosuppression is warranted. Thirdly, the antibody profile detected can help predict the cancer type. Fourthly, this testing can be used to investigate GI dysmotility occurring during cancer therapy that was not explainable by recurrent cancer or metastasis.
This then can help distinguish autoimmune GI dysmotility from chemotherapy side effects. Finally, a rising antibody titer in a previously seropositive patient can suggest cancer recurrence.
In summary, the autoimmune GI dysmotility serological evaluation aids the investigation of new onset idiopathic GI dysmotility. Detection of one or more of this profile of autoantibodies may lead to detection of unsuspected cancer and seropositivity will indicate a potentially immunotherapy responsive disorder.